Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Comprehensive Loss

v3.22.2
Consolidated Statements of Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]      
Revenues $ 568,704 $ 761,319 $ 478,520
Cost of revenues 271,817 307,713 236,493
Amortization of intangible assets 428,431 428,434 428,431
Gross loss (income) 131,544 (25,172) 186,404
Research and development 783,665 926,697 987,444
Less - research and development grants (315,967) (525,838) (256,423)
Research and development, net 467,698 400,859 731,021
Sales and marketing 625,031 673,986 673,983
General and administrative 1,345,495 1,414,370 1,319,239
Goodwill impairment 265,089
Total operating expenses 2,438,224 2,754,304 2,724,243
Operating loss 2,569,768 2,729,132 2,910,647
Financial expenses (income), net (50,904) 9,814,605 1,042,358
Net loss $ 2,518,864 $ 12,543,737 $ 3,953,005
Basic and diluted net loss per ordinary share (in Dollars per share) $ 0.06 $ 0.49 $ 0.16
Weighted average number of ordinary shares used in computing basic and diluted net loss per ordinary share (in Shares) 44,453,153 25,581,000 24,071,186